Literature DB >> 34742392

Manufacturing plant-made monoclonal antibodies for research or therapeutic applications.

Kelsi Swope1, Josh Morton2, Gregory P Pogue2, Steve Hume2, Michael H Pauly3, John Shepherd2, Carrie A Simpson2, Barry Bratcher2, Kevin J Whaley4, Larry Zeitlin4, Keith R Davis5, Hugh Haydon2.   

Abstract

Monoclonal antibodies (mAbs) hold great promise for treating diseases ranging from cancer to infectious disease. Manufacture of mAbs is challenging, expensive, and time-consuming using mammalian systems. We describe detailed methods used by Kentucky BioProcessing (KBP), a subsidiary of British American Tobacco, for producing high quality mAbs in a Nicotiana benthamiana host. Using this process, mAbs that meet GMP standards can be produced in as little as 10 days. Guidance for using individual plants, as well as detailed methods for large-scale production, are described. These procedures enable flexible, robust, and consistent production of research and therapeutic mAbs.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Drug manufacture; Infectious disease; Nicotiana benthamiana; Plant-made pharmaceuticals; Protein purification; Therapeutic

Mesh:

Substances:

Year:  2021        PMID: 34742392     DOI: 10.1016/bs.mie.2021.05.011

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  1 in total

1.  Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana.

Authors:  Kelsi Swope; Josh Morton; Gregory P Pogue; Leigh Burden; Nicholas Partain; Steve Hume; John Shepherd; Carrie A Simpson; Miles B Brennan; Thomas C Furman; Sheila Kingrey-Gebe; Theresa Martinez; Jim McDonough; Michael H Pauly; Kevin J Whaley; Larry Zeitlin; Barry Bratcher; Hugh Haydon
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.